Essential Considerations for Bone Modifying Agents in Oncology

This chapter stresses the significance of knowing creatinine clearance cutoffs for bone modifying agents and the necessity of dental clearance to prevent osteonecrosis of the jaw. It discusses the risks associated with osteoclasts inhibitor therapies like osteonecrosis of the jaw, dental examinations prior to treatment, dosages for different agents, monitoring calcium and vitamin D levels, and correcting deficiencies before initiating treatment.